

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
4 October 2001 (04.10.2001)

PCT

(10) International Publication Number
WO 01/72329 A1

- (51) International Patent Classification⁷: **A61K 39/00**, (74) Agents: **LICATA, Jane, Massey et al.**; Licata & Tyrrell
A01N 63/00 P.C., 66 E. Main Street, Marlton, NJ 08053 (US).
- (21) International Application Number: **PCT/US01/09736** (81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ,
(22) International Filing Date: 26 March 2001 (26.03.2001) DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
(25) Filing Language: English LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ,
NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM,
(26) Publication Language: English TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (30) Priority Data: (84) Designated States (*regional*): ARIPO patent (GH, GM,
09/537,642 29 March 2000 (29.03.2000) US KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
09/735,450 13 December 2000 (13.12.2000) US patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): **THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA** [US/US]; Center for Technology Transfer, Suite 300, 3700 Market Street, Philadelphia, PA 19107 (US).
- (72) Inventors; and
(75) Inventors/Applicants (*for US only*): **PATERSON, Yvonne** [US/US]; 514 South 46th Street, Philadelphia, PA 19143 (US). **GUNN III, George, Raymond** [US/US]; Apartment G14, 218 North Easton Road, Glenside, PA 19038 (US). **PETERS, Christian** [DE/US]; 429 King of Prussia Road, Radnor, PA 19087 (US).
- Published:**
— *with international search report*
— *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments*
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 01/72329 A1

(54) Title: COMPOSITIONS AND METHODS FOR ENHANCING IMMUNOGENICITY OF ANTIGENS

(57) Abstract: Compositions and methods for enhancing the immunogenicity of an antigen via fusion to a non-hemolytic truncated form of listeriolysin or a PEST-like amino acid sequence derived from a prokaryotic organism are provided.

- 1 -

COMPOSITIONS AND METHODS FOR ENHANCING IMMUNOGENICITY OF ANTIGENS

Introduction

This invention was supported in part by funds from the
5 U.S. government (NIH Grant No. CA69632) and the U.S.
government may therefore have certain rights in the invention.

Background of the Invention

Stimulation of an immune response is dependent upon the
presence of antigens recognized as foreign by the host immune
10 system. Bacterial antigens such as *Salmonella enterica* and
Mycobacterium bovis BCG remain in the phagosome and stimulate
CD4 T-cells via antigen presentation through major
histocompatibility class II molecules. In contrast, bacterial
antigens such as *Listeria monocytogenes* exit the phagosome
15 into the cytoplasm. The phagolysosomal escape of *L.*
monocytogenes is a unique mechanism which facilitates major
histocompatibility class I antigen presentation of listerial
antigens. This escape is dependent upon the pore-forming
sulfhydryl-activated cytolysin, listeriolysin O (LLO).

20 The ability of *L. monocytogenes* to break down the
vacuole within a host cell and enter the cytoplasm has led to
its use as a recombinant vaccine. U.S. Patent 5,830,702
describes vaccines comprising attenuated mutants of *Listeria*
spp. genetically engineered to express foreign antigens in the
25 cytoplasm of infected macrophages and other cells. Several
approaches for expressing the antigen in *Listeria spp.* are
described including generation of a fusion protein of a
selected foreign antigen and a listerial protein, preferably
an enzyme involved in lysis of host vacuoles. In particular,
30 a fusion protein encoding the *hly* promoter and the first 416
amino acids of LLO fused in-frame to the entire coding

- 2 -

transformation to *Listeria monocytogenes* is demonstrated to secrete a 105 kDA protein that reacts with antiserum to LLO and NP (col. 24 of '702 patent). Recombinant *L. monocytogenes* secreting a fusion protein comprising listeriolysin O and NP 5 (LLO-NP) was demonstrated to target infected cells for lysis by NP-specific class I-restricted cytotoxic T cells. In contrast, a hemolysin-negative *L. monocytogenes* strain expressing LLO-NP presented the antigen in a class II restricted manner (Ikonimidis et al. *J. Exp. Med.* 1994 10 180:2209-2218). Thus, from these studies it was surmised that hemolysin-dependent bacterial escape from the vacuole is necessary for class I presentation *in vitro*.

The escape function of *L. monocytogenes* has also been transferred to *Bacillus subtilis* and attenuated *Salmonella* 15 *ssp.* strains (Bielecki et al. *Nature* 1990 354:175-176, Gentshev et al. *Infect. Immun.* 1995 63:4202-4205). *S. enteric* and *M. bovis* BCG vaccine carriers which secrete listeriolysin O have also been constructed (Kaufman, S.H. and Hess, J. *Immunol. Lett.* January 1999 65(1-2):81-4). These 20 constructs are taught to be capable of introducing antigens into the MHC class II and MHC class I pathway, resulting in stimulation of both CD4 and CD8 T-cells. Comparison of *S. enterica* vaccines which display the same listerial antigen in secreted and somatic form showed the secreted antigen display 25 to be superior to the somatic antigen display (Kaufman, S.H. and Hess, J. *Immunol. Lett.* January 1999 65(1-2):81-4).

WO 99/10496 discloses recombinant BCG strains secreting hemolytically active hly with an improved MHC class I-restricted immune response for use as a vaccine against 30 tuberculosis.

Administration of purified listeriolysin O encapsulated in liposomes has also been reported to be effective in the induction of antigen-specific Th1-dependent protective immunity to various kinds of intracellular parasitic bacteria 35 *in vivo* (Tanabe et al. *Infect. Immun.* February 1999 67(2):568-

- 3 -

in vivo (Tanabe et al. *Infect. Immun.* February 1999 67(2):568-75). PEST sequences in eukaryotic proteins have long been identified. It has been taught that proteins containing amino acid sequences that are rich in prolines (P), glutamic acids (E), serines (S) and threonines (T), generally, but not always, flanked by clusters containing several positively charged amino acids, have rapid intracellular half-lives (Rogers et al. *Science* 1986 234:364-369). Further, it has been shown that these sequences target the protein to the ubiquitin-proteosome pathway for degradation (Rechsteiner and Rogers *TIBS* 1996 21:267-271). This pathway is also used by eukaryotic cells to generate immunogenic peptides that bind to MHC class I and it has been hypothesized that PEST sequences are abundant among eukaryotic proteins that give rise to immunogenic peptides (Realini et al. *FEBS Lett.* 1994 348:109-113). Prokaryotic proteins do not normally contain PEST sequences because they do not have this enzymatic pathway.

However, a PEST-like sequence rich in the amino acids proline (P), glutamic acid (E), serine (S) and threonine (T) was recently identified at the amino terminus of LLO and demonstrated to be essential for *L. monocytogenes* pathogenicity (Decatur, A.L. and Portnoy, D.A. *Science* 2000 290:992-995). Decatur and Portnoy teach that the presence of this PEST-like sequence in LLO targets the protein for destruction by proteolytic machinery of the host cell so that once the LLO has served its function and facilitated the escape of *L. monocytogenes* from the phagolysosomal vacuole, it is destroyed before it can damage the cells.

It has now been found that the immune response to an antigen can be enhanced by fusion of the antigen to a non-hemolytic truncated form of listeriolysin O (Δ LLO). It is believed that the observed enhanced cell mediated immunity and anti-tumor immunity of the fusion protein results from the

- 4 -

Summary of the Invention

An object of the present invention is to provide a method for enhancing the immunogenicity of an antigen which comprises fusing to the antigen a non-hemolytic truncated form of listeriolysin O (Δ LLO). In a preferred embodiment, the antigen is fused to a PEST-like amino acid sequence derived from *L. monocytogenes*.

Another object of the present invention is to provide compositions with enhanced cell mediated immunity and anti-tumor immunity which comprise an antigen fused to a PEST-like amino acid sequence derived from a prokaryotic organism.

Yet another object of the present invention is to provide a method for invoking an enhanced cell mediated or anti-tumor immunogenic response to an antigen in an animal comprising administering to the animal a composition comprising an antigen fused to a PEST-like amino acid sequence derived from a prokaryotic organism.

Brief Description of the Drawings

Figure 1 is a diagram of an HPV-E7 chromosomal expression system constructed by integration of an E7 gene into the *Listeria* chromosome.

Figure 2 is a diagram of a preferred multi-copy plasmid containing *prfA* and E7 fused to a truncated form of the *hly* gene (Δ hly) that produced Δ LLO.

Figure 3 is a diagram of various Vaccinia virus constructs expressing different forms of HPV16 E7 protein.

Detailed Description of the Invention

The present invention relates to a method for enhancing the immunogenicity of a selected antigen by fusion of the selected antigen to a non-hemolytic truncated form of listeriolysin O. It has now been found that fusion of an antigen to a non-hemolytic truncated form of listeriolysin O results in an antigen with enhanced immunogenicity as compared

- 5 -

to antigen alone. This truncated form of listeriolysin O fused to an antigen better enables cell mediated immunity and anti-tumor immunity as compared to antigen alone. Further, these fusion proteins need not be expressed by *L. monocytogenes*, but rather can be expressed and isolated from other vectors and cell systems routinely used for protein expression and isolation.

Listeriolysin O (LLO) binds to cholesterol-containing membranes wherein it oligomerizes to form pores. The oligomerization is dependent on the presence of a reduced cystine residue at position 484 in the sequence that is required for oligomerization. The *hly* gene encodes a proprotein of 529 residues (GenBank Accession No. P13128), the first 25 amino acids are the signal sequence and are cleaved from LLO when it is secreted by the bacterium. Thus, the full length active LLO protein is approximately 504 residues. For purposes of the present invention, by "truncated form of LLO or ΔLLO" it is meant a fragment of LLO which does not contain the activation domain at the amino terminus including cystine 484.

The present invention also relates to methods and compositions for enhancing cell mediated or anti-tumor immunity of a selected antigen by fusion of the selected antigen to a PEST-like amino acid sequence derived from a prokaryotic organism. For purposes of the present invention, by "PEST-like amino acid sequence" it is meant a peptide rich in the amino acids proline (P), glutamic acid (E), serine (S) and threonine (T). In a preferred embodiment the PEST-like amino acid sequence is derived from the amino acid terminus of Listeriolysin O (LLO), a hemolytic virulence factor of *L. monocytogenes*. In a more preferred embodiment, the PEST-like amino acid sequence comprises KENSISSMAPPASPPASPKTPIEKKHAEIDK (SEQ ID NO:1).

Enhanced cell mediated immunity was demonstrated for fusion proteins comprising an antigen and truncated LLO containing the PEST-like amino acid sequence, SEQ ID NO:1.

- 6 -

The Δ LLO used in these experiments was 416 amino acids long as 88 residues from the amino terminus which is inclusive of the activation domain containing cystine 484 were truncated. However, it is believed that other Δ LLOs without the activation domain, and in particular cystine 484, will also be effective. More particularly, it is believed that fusion of an antigen to any Δ LLO including the PEST-like amino acid sequence, SEQ ID NO:1, can enhance cell mediated and anti-tumor immunity of the antigen.

- 10 Enhanced immunogenicity of an antigen following fusion to a non-hemolytic truncated form of listeriolysin O was demonstrated. Specifically, experiments have been performed demonstrating that an *L. monocytogenes* vector that expresses and secretes a fusion product of Human Papilloma Virus (HPV) strain 16 E7 and listeriolysin, which comprises the PEST-like amino acid sequence SEQ ID NO:1, is a much more potent cancer immunotherapeutic for HPV immortalized tumors than a strain of *L. monocytogenes* that secretes the E7 protein alone. Experiments were also performed demonstrating that a recombinant vaccinia virus that carries the gene for the fusion protein LLO-E7 which contains the PEST-like amino acid sequence of SEQ ID NO:1 is a much more potent cancer immunotherapeutic for HPV immortalized tumors than an isogenic strain of vaccinia that carries the gene for E7 protein alone.
- 20 In comparison, a short fusion protein Lm-AZ/-E7 comprising the E7 antigen fused to the promoter, signal sequence and the first 7 amino acid residues of LLO was an ineffective anti-tumor immunotherapeutic. This short fusion protein terminates directly before the PEST-like sequence and does not contain it. In a first set of experiments, the HPV-E7 antigen was expressed in *L. monocytogenes*. An *L. monocytogenes* recombinant that expressed E7 was made by chromosomal integration of the E7 gene under the control of the *hly* promoter and with the inclusion of the *hly* signal sequence to ensure secretion of the gene product. The site of integration
- 30
- 35

- 7 -

into the chromosome by homologous recombination was into a region that is non-essential for Lm virulence. The scheme for this is depicted in Figure 1. The advantage in using this type of transformation is that resulting recombinants are stably transformed and contain no drug selection markers since the CAT gene, included in the plasmid to select for successful transformants after electroporation, is excised during a second recombination event. The expression and secretion of the antigen from the resulting recombinants, Lm-E7, was verified by Western Blot. In addition, therapeutic effects of Lm-E7 were optimized. For example, it was found that the best results were achieved delivering the vaccine orally as compared to parenterally and in a combined protection and regression mode that requires priming with Lm-E7 before tumor challenge and then administering Lm-E7 therapeutically after tumor challenge. Table 1 provides more details for optimized anti-tumor effects observed in this model in three different tumor cell lines, TC-1, C3 and EL-4/E7. Bacteria were delivered orally 14 and 7 days prior to tumor challenge and 7 and 14 days following tumor challenge. Delivery of 10^6 bacteria intraperitoneally in a similar protocol provided no long-term protection. However, better protection was observed when Lm-E7 was delivered orally. More specifically, with this regimen approximately 50% of the animals remained tumor free in perpetuity and immunization seriously retarded tumor growth in all animals.

Table 1: Treatment with Lm-E7

Treatment	Number of tumor free animals versus total in study (number survived)		
	10^5 TC-1 on day 60	10^6 C3 on day 42	5×10^5 EL-4/E7 on day 40
10^8 Lm-E7	3/8 (5)	4/8 (8)	4/8 (6)
10^8 Lm-Gag(ZY-18)	2/8 (2)	0/8 (0)	2/8 (0)
Naive	0/8 (0)	0/8 (0)	1/8 (0)

- 8 -

Animals administered TC-1 or EL-4/E7 tumor cells that were tumor free were re-challenged on day 60 with TC-1 or day 40 EL-4/E7, respectively. The two animals in each group that had
5 been immunized with Lm-Gag grew tumors whereas the animals immunized with Lm-E7 remained tumor free until termination of the experiment (day 124 in the case of TC-1 and day 54 for EL-4/E7).

Compared to results previously disclosed with Lm-NP and
10 the RENCA, CT-26 and B16F10-NP models (Pan et al. 1995), the Lm-E7 was less effective than expected. Accordingly, an Lm-E7 construct was prepared in accordance with the method taught for preparation of the Lm-NP construct of Pan et al. (Cancer Res. 1995 55:4776-4779).

15 Specifically, a second *L. monocytogenes* vaccine that expresses a E7 fusion protein, referred to as Lm-LLO-E7, was prepared by complementing a *prfA*-deletion mutant with a plasmid containing a copy of the *prfA* gene and a copy of the E7 gene fused to a form of the *hly* gene truncated to eliminate
20 the hemolytic activity of the enzyme, Δ LLO (see Figure 2).

Functional LLO is maintained by the organism via the endogenous chromosomal copy of *hly*. The expression and secretion of the fusion protein was verified by Western blot.

The ability of the Lm-LLO-E7 and Lm-E7 vaccine to induce
25 anti-tumor immunity was then compared in a regression model. As shown in Table 2, Lm-LLO-E7 was found to be more effective than Lm-E7. This difference in efficacy is believed to be due to the presence of the PEST-like sequence, SEQ ID NO:1, in Lm-LLO-E7.

- 9 -

Table 2: Number of mice cured of TC-1 tumor at conclusion of experiment

Treatment	Mice TC-1 free at day 45	Mice alive at day 45	Mice alive at day 134
Naive	0/8	0/8	0/8
5 Lm-LLO-E7	4/8	8/8	4/8
Lm-E7	0/8	7/8	0/8

Thus, expression of the foreign gene as a fusion protein with Δ LLO enhances the immunogenicity of the antigen.

Additional experiments were performed to compare the ability of Lm-E7 with Lm-LLO-E7 to induce the regression of established sub-cutaneous HPV-16 immortalized tumors from C57Bl/6 mice. In these experiments, mice were immunized i.p. with 0.1 LD₅₀ with one of four constructs, Lm-E7, Lm-Gag (isogenic with Lm-E7 except for the antigen expressed), Lm-LLO-E7 or Lm-LLO-NP. Lm-LLO-NP is isogenic with Lm-LLO-E7 but expresses influenza antigen. A second immunization was performed on day 14. Six of eight mice immunized with Lm-LLO-E7 were cured of their tumors and remained tumor free. None of the other animals showed any regression of the established tumors. Similar results have been achieved for Lm-LLO-E7 under different immunization protocols. Further, just one immunization has been demonstrated to cure mice of established TC-1 of 5 mm diameter.

In order to confirm the generality of the finding that fusing LLO to an antigen confers enhanced immunity, a version of Lm-NP similar to Lm-E7 was constructed. This recombinant was prepared as shown in Figure 1 except that influenza nucleoprotein replaced E7 as the antigen. The ability of the new Lm-NP was compared with Lm-LLO-NP (described in U.S. Patent 5,830,702 and prepared as shown in Figure 2). In these experiments, 32 BALB/c mice were inoculated with 5×10^5 RENCA-NP tumor cells. RENCA-NP is a renal cell carcinoma

- 10 -

retrovirally transduced with influenza nucleoprotein NP (described in U.S. Patent 5,830,702). After palpable macroscopic tumors had grown on day 10, eight animals in each group were immunized i.p. with 0.1LD₅₀ with one of three
5 constructs, Lm-NP, Lm-Gag (isogenic with Lm-NP except for the antigen expressed) and Lm-LLO-NP. The animals received a second immunization one week later. Eight animals were left untreated. At the end of the experiment on day 40, all the mice in the naive group had large tumors or had died. Only
10 one mouse in the group that received Lm-Gag and two mice in the group that received Lm-NP were tumor free. This experiment shows that fusing an antigen to LLO is not restricted to E7 and suggests that the form of the antigen is not important.

15 Additional experiments were performed to confirm the enhanced therapeutic efficacy of a fusion protein comprising the E7 antigen and a truncated form of listeriolysin O. In these experiments a vaccinia vector that expresses E7 as a fusion protein with a non-hemolytic truncated form of
20 listeriolysin O was constructed. The WR strain of vaccinia was used as the recipient and the fusion gene was excised from the listerial plasmid and inserted into pSC11 under the control of the p75 promoter. This vector was chosen because it is the transfer vector used for the vaccinia constructs
25 Vac-SigE7Lamp and Vac-E7 and would therefore allow direct comparison with Vac-LLO-E7. In this way all three vaccinia recombinants would be expressed under control of the same early/late compound promoter p7.5. In addition SC11 allows the selection of recombinant viral plaques to TK selection and
30 β -galactosidase screening.

Figure 3 shows the various vaccinia constructs used in these experiments. Vac-SigE7Lamp is a recombinant vaccinia virus that expressed the E7 protein fused between lysosomal associated membrane protein (LAMP-1) signal sequence and
35 sequence from the cytoplasmic tail of LAMP-1 (Lin et al. *Proc.*

- 11 -

Natl. Acad. Sci. USA 1995 92:11671-5; Wu et al. Cancer Res. 1996 56:21-6). It was designed to facilitate the targeting of the antigen to the MHC class II pathway.

The following modifications were made to allow
5 expression of the gene product by vaccinia: (a) the T5XT sequence that prevents early transcription by vaccinia was removed from the 5' portion of the LLO-E7 sequence by PCR; and (b) an additional *XmaI* restriction site was introduced by PCR to allow the final insertion of LLO-E7 into SC11. Successful
10 introduction of these changes (without loss of the original sequence that encodes for LLO-E7) was verified by sequencing. The resultant pSC11-E7 construct was used to transfect the TK-ve cell line CV1 that had been infected with the wildtype vaccinia strain, WR. Cell lysates obtained from this co-
15 infection/transfection step contain vaccinia recombinants that were plaque purified 3 times. Expression of the LLO-E7 fusion product by plaque purified vaccinia was verified by Western blot using an antibody directed against the LLO protein sequence. In addition, the ability of Vac-LLO-E7 to produce
20 CD8+ T cells specific to LLO and E7 was determined using the LLO(91-99) and E7(49-57) epitopes of Balb/c and C57/BL6 mice, respectively. Results were confirmed in a chromium release assay.

Tumor rejection studies were performed with TC-1
25 following the same protocol as described *supra*. Two experiments were performed with differing delays before treatment was started. In one experiment, treatments were initiated when the tumors were about 3 mm in diameter. As of day 76, 50% of the Vac-LLO-E7 treated mice are tumor free and
30 25% of the Vac-SigE7Lamp mice are tumor free.

In the second experiment, TC-1 tumors were grown to a larger size (5 to 6 mm). The LLO-E7 fusion protein based vectors were then compared against a larger number of vectors. Although some of the vaccine groups showed significant
35 temporary regression of TC-1, by day 65 the data clearly shows

- 12 -

that Lm-LLO-E7 and Vac-LLO-E7 are the most effective vaccines with respect to the ability to permanently induce the regression of established TC-1. Only 12% of the Vac-SigE7Lamp treated mice were tumor free while 37% of the Vac-LLO-E7 and 5 Lm-LLO-E7 mice were tumor free. All other mice were dead.

Thus, expression of the antigen as a fusion protein with a non-hemolytic truncated form of listeriolysin O in host cell systems in listeria and host cell systems other than listeria results in enhanced immunogenicity of the antigen. While 10 comparative experiments were performed with vaccinia, a multitude of other plasmids and expression systems which can be used to express these fusion proteins are known. For example, bacterial vectors useful in the present invention include, but are not limited to *Salmonella sp.*, *Shigella sp.*, 15 BCG, *L. monocytogenes* and *S. gordonii*. In addition the fusion proteins can be delivered by recombinant bacterial vectors modified to escape phagolysosomal fusion and live in the cytoplasm of the cell. Viral vectors useful in the present invention include, but are not limited to, Vaccinia, Avipox, 20 Adenovirus, AAV, Vaccinia virus NYVAC, Modified vaccinia strain Ankara (MVA), Semliki Forest virus, Venezuelan equine encephalitis virus, herpes viruses, and retroviruses. Naked DNA vectors can also be used.

Accordingly, the present invention provides methods for 25 enhancing the immunogenicity of an antigen via fusion of the antigen to a non-hemolytic truncated form of listeriolysin O or Δ LLO. In a preferred embodiment, the antigen is fused to the PEST-like amino acid sequence, SEQ ID NO:1, of LLO.

The present invention also provides methods for 30 enhancing cell mediated and anti-tumor immunity and compositions with enhanced immunogenicity which comprise a PEST-like amino acid sequence derived from a prokaryotic organism fused to or embedded within an antigen. The PEST-like sequence can be fused to either the amino terminus or the 35 carboxy terminus of the antigen. As demonstrated herein,

- 13 -

fusion of an antigen to the PEST-like sequence of *L. monocytogenes* enhanced cell mediated and anti-tumor immunity of the antigen. It is believed that fusion of an antigen to other PEST-like sequences derived from other prokaryotic organisms will also enhance immunogenicity of the antigen. PEST-like sequence of other prokaryotic organism can be identified routinely in accordance with methods such as described by Rechsteiner and Roberts (TBS 21:267-271,1996) for *L. monocytogenes*. Alternatively, PEST-like amino acid sequences from other prokaryotic organisms can also be identified based by this method. Other prokaryotic organisms wherein PEST-like amino acid sequences would be expected to include, but are not limited to, other *Listeria* species. For example, the *L. monocytogenes* protein ActA contains four such sequences. These are KTEEQPSEVNTGPR (SEQ ID NO:2), KASVTDTSEGDLDSSMQSADESTPQPLK (SEQ ID NO:3), KNEEVNASDFPPPPTDEELR (SEQ ID NO:4), and RGGIPTSEEFSSLNSGDFDENSETTEEEIDR (SEQ ID NO:5). Also Streptolysin O from *Streptococcus sp.* contain a PEST-LIKE sequence. For example, *Streptococcus pyogenes* Streptolysin O comprises the PEST-like sequence KQNTASTETTTTNEQPK (SEQ ID NO:6) at amino acids 35-51 and *Streptococcus equisimilis* Streptolysin O comprises the PEST-like sequence KQNTANTETTTTNEQPK (SEQ ID NO:7) at amino acids 38-54. Further, it is believed that the PEST-like sequence can be embedded within the antigenic protein. Thus, for purposes of the present invention, by "fusion" it is meant that the antigenic protein comprises both the antigen and the PEST-like amino acid sequence either linked at one end of the antigen or embedded within the antigen.

In a preferred embodiment, fusion proteins of the present invention are produced recombinantly via a plasmid which encodes either a truncated form of the listeriolysin O comprising the PEST-like amino acid sequence of *L. monocytogenes* or a PEST-like amino acid sequence derived from

- 14 -

another prokaryotic organism and the antigen. However, the antigen may also be chemically conjugated to the truncated form of listeriolysin O comprising the PEST-like amino acid sequence of *L. monocytogenes* or a PEST-like amino acid sequence derived from another prokaryotic organism. For purposes of the present invention, by "antigen" it is meant to include the native antigen gene or gene product or truncated versions of these that include identified T cell epitopes. These fusion proteins can then be incorporated into vaccines for administration to animals, preferably humans, to invoke an enhanced immune response against the antigen of the fusion protein. In one embodiment, the fusion proteins of the present invention are delivered as DNA vaccines, RNA vaccines or replicating RNA vaccines. As will be obvious to those of skill in the art upon this disclosure, vaccines comprising the fusion proteins of the present invention are particularly useful in the prevention and treatment of infectious and neoplastic diseases.

These vaccines may further comprise adjuvants. Examples of adjuvants useful in these vaccines include, but are not limited to, unmethylated CpG, quill glycosides, CFA, QS21, monophosphoryl lipid A, liposomes, and bacterial mitogens and toxins.

The following examples are provided for illustrative purposes only and are not intended to limit the invention.

EXAMPLES

Example 1: Tumor cell lines

TC-1 is a lung epithelial cell from C57BL/6 mice immortalized by HPV-16 E6 and E7 and transformed by pVEJB expressing activated human c-HA-ras. C3 is a mouse embryo cell frp, C57BL/6 mice immortalized with the complete genome of HPV16 and transformed with pEJ-ras. EL-4/E7 is the thymoma EL-4 retrovirally transduced with E7.

- 15 -

Example 2: Comparison of efficacy of Lm-GG/E7, Lm-AZ/E7 and Vac-SigE7Lamp

TC-1 (1×10^5) or C-3 (5×10^5) tumor cells were implanted subcutaneously in mice and allowed to grow for 7 to 9 days by which time they were palpable (~5 mm in size). Mice were then immunized i.p. with one of three constructs, Vac-SigE7Lamp (10^7 PFU), Lm-E7 (10^6 CFU) or Lm-LLO-E7 (10^7 CFU). Animals received Lm-LLO-E7 and Lm-E7 on days 7 and 14. Surviving mice were re-challenged with 10^5 TC-1 on day 43.

10 **Example 3: Comparison of efficacy of Vac-LLO-E7, Vac-E7 and Vac-SigE7Lamp**

Four groups of 8 mice were implanted with 10^5 cells of TC-1. After 7 days the tumors were approximately 4 mm in size. One group of mice was untreated. Each of the other 15 groups received 10^7 PFU of either Vac-E7, Vac-LLO-E7 or Vac-Sig-E7-lamp 7. A booster dose was administered on day 14.

Example 4: Comparison of efficacy of Vac-LLO-E7 and Lm-LLO-E7 with various other vectors

TC-1 tumor cells (2×10^5) were implanted s.c. on the 20 left flank in 96 C57BL/6 mice and allowed to grow for 7 days. The mice were divided into groups of 8 mice and each group was treated with one of the following vaccine: naive (no vaccine); Vac SigE7Lamp, 10^7 PFU, i.p.; Vac-LLO-E7, 10^7 PFU, i.p.; or Lm-LLO-E7, 10^7 PFU, i.p. The animals received a booster 25 immunization one week later. Tumor growth was followed every two days by caliper measurement and recorded as the average of the narrowest and longest surface length. Immune parameters were also determined.

Example 5: Construction of Lm-LLOPEST-E7

30 The LLO-PEST-E7 fragment can be constructed via SOEing PCR.

In Step 1 of this method, PCR reaction 1 uses primer pair GG-36/GG-78 or GG-77/AZ-9 with pGG-55 for the template. PCR reaction 2 uses LLO-PEST and E7 products from the first 35 reaction as templates and the primers GG-36 and AZ-9.

- 16 -

GG-36: 5'-GCTAGCCCTCCTTTGATTAGTATATTC-3' (SEQ ID NO:8)

GG-77: 5'-GCGGATGAAATCGATAAGCATGGAGATACACCTACA-3' (SEQ ID NO:9)

GG-78: 3'-CGCCTACTTTAGCTATTCGTACCTCTATGTGGATGT-5' (SEQ ID NO:10)

AZ-9: 3'-GAGTCTTTGGTATTGGGCCC-5' (SEQ ID NO:11)

In step 2, the final SOEing PCR product of 0.7 Kb is ligated into the TA vector pCR2.1.

In step 3, the LLO-PEST-E7 is digested from the plasmid with the enzyme NheI for 2 hours followed by ethanol precipitation and the enzyme XmaI overnight. The prfA fragment from pGG-49 is digested with the enzyme SalI for 2 hours followed by ethanol precipitation and XmaI overnight. pDP-2028 is digested with SalI and XbaI for 2 hours followed by ethanol precipitation and resuspension in Tris:EDTA (TE). The fragment can be stored overnight at 4°C.

In step 4, the 0.7 Kb LLO-PEST-E7, 1.0 Kb prfA and the 9.7 Kb plasmid are ligated. This plasmid is then used to transform XFL-7. Secretion of a 15 Kb fragment can be verified via Western blot. Efficacy is verified against TC-1 tumors.

Alternatively, a chromosomal integrant can be generated by amplifying the LLO-PEST-E7 fragment using the primer AZ-B (5'-GCTCTAGATTATGGTTTCTGAG-3'; SEQ ID NO:12) to install a 3' XbaI site and primer ZY-3 (5'-GGGGTACCCTCCTTTGATTAGTATAT-3'; SEQ ID NO:13) to install a 5' KpnI site. pZY-37 and the LLO-PEST-E7 fragment are digested with KpnI and XbaI separately or in NEB buffer 2+ BSA overnight. The fragment is ligated into pZY-37 and the following protocol for chromosomal integration is followed. Secretion and efficacy are verified as described above.

- 17 -

What is claimed is:

1. A method for enhancing the immunogenicity of an antigen comprising fusing to the antigen a non-hemolytic truncated form of listeriolysin O.
- 5 2. The method of claim 1 wherein the non-hemolytic truncated form of listeriolysin comprises a PEST-like amino acid sequence.
3. The method of claim 3 where the PEST-like amino acid sequence comprises SEQ ID NO:1.
- 10 4. The method of claim 1 wherein the non-hemolytic truncated form of listeriolysin O is fused to the antigen by recombinant expression of a plasmid encoding the truncated form of the listeriolysin O and the antigen.
5. A composition with enhanced cell mediated immunity
15 and anti-tumor immunity comprising a PEST-like amino acid sequence derived from a prokaryotic organism fused to or embedded within an antigen.
6. The composition of claim 5 wherein the PEST-like amino acid sequence is derived from a *Listeria* species.
- 20 7. The composition of claim 6 wherein the PEST-like amino acid sequence is derived from *Listeria monocytogenes*.
8. The composition of claim 5 wherein the PEST-like amino acid sequence comprises SEQ ID NO:1.
9. The composition of claim 5 wherein the PEST-like
25 sequence comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 2, 3, 4, 5, 6 and 7.

- 18 -

10. A method for invoking an enhanced cell mediated or anti-tumor immunogenic response to an antigen in an animal comprising administering to the animal a composition of claim 5.

5 11. A vaccine for invoking an enhanced cell mediated or anti-tumor immunogenic response to an antigen comprising a composition of claim 5.

12. The vaccine of claim 11 further comprising an adjuvant.




FIG. 1

2 / 3




FIG. 2




FIG. 3

SEQUENCE LISTING

<110> Paterson, Yvonne
Gunn III, George R
Peters, Christian
The Trustees of the University of Pennsylvania

<120> Compositions and Methods for Enhancing Immunogenicity
of Antigens

<130> PENN-0756

<140>

<141>

<150> 09/537,642

<151> 2000-03-29

<150> 09/735,450

<151> 2000-12-13

<160> 13

<170> PatentIn Ver. 2.1

<210> 1

<211> 32

<212> PRT

<213> *Listeria monocytogenes*

<400> 1

Lys Glu Asn Ser Ile Ser Ser Met Ala Pro Pro Ala Ser Pro Pro Ala
1 5 10 15

Ser Pro Lys Thr Pro Ile Glu Lys Lys His Ala Asp Glu Ile Asp Lys
20 25 30

<210> 2

<211> 14

<212> PRT

<213> *Listeria monocytogenes*

<400> 2

Lys Thr Glu Glu Gln Pro Ser Glu Val Asn Thr Gly Pro Arg

1

5

10

<210> 3

<211> 28

<212> PRT

<213> Listeria monocytogenes

<400> 3

Lys Ala Ser Val Thr Asp Thr Ser Glu Gly Asp Leu Asp Ser Ser Met

1

5

10

15

Gln Ser Ala Asp Glu Ser Thr Pro Gln Pro Leu Lys

20

25

<210> 4

<211> 20

<212> PRT

<213> Listeria monocytogenes

<400> 4

Lys Asn Glu Glu Val Asn Ala Ser Asp Phe Pro Pro Pro Pro Thr Asp

1

5

10

15

Glu Glu Leu Arg

20

<210> 5

<211> 33

<212> PRT

<213> Listeria monocytogenes

<400> 5

Arg Gly Gly Ile Pro Thr Ser Glu Glu Phe Ser Ser Leu Asn Ser Gly

1

5

10

15

Asp Phe Thr Asp Asp Glu Asn Ser Glu Thr Thr Glu Glu Glu Ile Asp

20

25

30

Arg

<210> 6

<211> 17

<212> PRT

<213> Streptococcus pyogenes

<400> 6

Lys Gln Asn Thr Ala Ser Thr Glu Thr Thr Thr Thr Asn Glu Gln Pro
1 5 10 15

Lys

<210> 7

<211> 17

<212> PRT

<213> Streptococcus equisimilis

<400> 7

Lys Gln Asn Thr Ala Asn Thr Glu Thr Thr Thr Thr Asn Glu Gln Pro
1 5 10 15

Lys

<210> 8

<211> 27

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 8

gctagccctc ctttgattag tatattc

27

<210> 9

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 9

gcggatgaaa tcgataagca tggagataca cctaca

36

<210> 10

<211> 36

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 10

cgctacttt agctattcgt acctctatgt ggatgt

36

<210> 11

<211> 20

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 11

gagtctttgg tattgggcc

20

<210> 12

<211> 22

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 12

gctctagatt atggtttctg ag

22

<210> 13

<211> 26

<212> DNA

<213> Artificial Sequence

<220>

<223> Description of Artificial Sequence: synthetic

<400> 13

ggggtaccct cctttgatta gtatat

26

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US01/09736

A. CLASSIFICATION OF SUBJECT MATTER																				
IPC(7) : A61K 39/00, A01N 63/00 US CL : 424/184.1, 424/93.1																				
According to International Patent Classification (IPC) or to both national classification and IPC																				
B. FIELDS SEARCHED																				
Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/184.1, 424/93.1																				
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched																				
Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Medline, Embase, Scisearch, Biosis, Caplus on STN, Pir_67, SwissProt_39, SPTREMBL_15																				
C. DOCUMENTS CONSIDERED TO BE RELEVANT																				
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.																		
Y	SIRARD et al. Intracytoplasmic delivery of Lidteriolysin O by a vaccinal strain of Bacillus anthracis induces CD8-mediated protection against listeria monocytogenes. J Immunology. November 1997, Vol. 159, pages 4435-4443, see page 4437, in particular.	1-8, 10, 11-12																		
Y	VERMA et al. Delivery of class I and class II MHC-restricted T-cell epitopes of listeriolyisin of listeria monocytogenes by attenuated salmonella. Vaccine. February 1995, Vol. 13, No. 2, pages 142-150, see pages 143-145, in particular.	1-8, 10, 11-12																		
Y	AN et al. A recombinant minigene vaccine containing a nonameric cytotoxic-T-Lymphocyte epitope confers limited protection against Listeria monocytogenes infection. Infect. Immun. May 1996, Vol.64, No.5, pages 1685-1693, see page 1686, in particular.	1-8, 10, 11-12																		
X	MORIISHI et al. Sequence analysis of the actA gene of Listeria monocytogenes isolated from human. Microbiol.-Immunol.-1998; Vol.42; No.2; pages 129-132; see entire document.	9																		
X	KOCKS et al. L. monocytogenes-induced actin assembly requires the actA gene product. Cell. February 1992, Vol.68, No.3, pages 521-531, see entire document.	9																		
X	MENGAUD et al. Expression in Escherichia coli and sequence analysis of the listeriolyisin O determinant of Listeria monocytogenes. Infect. Immun. April 1988, Vol.56, No. 4, pages 766-772, see entire document.	9																		
<input type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.																				
<table border="0"> <tr> <td colspan="2">* Special categories of cited documents:</td> <td>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</td> </tr> <tr> <td>"A" document defining the general state of the art which is not considered to be of particular relevance</td> <td>"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone</td> <td></td> </tr> <tr> <td>"B" earlier application or patent published on or after the international filing date</td> <td>"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art</td> <td></td> </tr> <tr> <td>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</td> <td>"&" document member of the same patent family</td> <td></td> </tr> <tr> <td>"O" document referring to an oral disclosure, use, exhibition or other means</td> <td></td> <td></td> </tr> <tr> <td>"P" document published prior to the international filing date but later than the priority date claimed</td> <td></td> <td></td> </tr> </table>			* Special categories of cited documents:		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention	"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone		"B" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art		"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family		"O" document referring to an oral disclosure, use, exhibition or other means			"P" document published prior to the international filing date but later than the priority date claimed		
* Special categories of cited documents:		"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention																		
"A" document defining the general state of the art which is not considered to be of particular relevance	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone																			
"B" earlier application or patent published on or after the international filing date	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art																			
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"&" document member of the same patent family																			
"O" document referring to an oral disclosure, use, exhibition or other means																				
"P" document published prior to the international filing date but later than the priority date claimed																				
Date of the actual completion of the international search		Date of mailing of the international search report																		
01 JULY 2001-07-03		27 JUL 2001																		
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231		Authorized officer Phuong N. Huynh																		
Facsimile No. (703) 305-3230		Telephone No. (703) 308-0196																		